1. First read about Kerydin Antifungal Topical Solution and learn more about its indications and  contraindications and read and agree to the Waiver of Liability.
2. Next, accurately and truthfully complete and submit a medical consultation questionnaire
3. Your medial consultation will be reviewed by one of our Physicians and if approved you will receive a Kerydin Topical Solution  prescription with  refills for the complete 48 week course of treatment which can be filled at most any local United States pharmacy of your choice. No medication purchase required- you can choose any pharmacy where your medical insurance accepted.
4. This physician evaluation is RISK-FREE.  If  Kerydin prescription is not appropriate for you there is No charge.  The initial consultation fee for the physician evaluation is only $49.95. 
5. If you choose EXPRESS service, your Kerydin prescription will be called into your local United States pharmacy within approximately 24 hours.  If Kerydin is not for you, the visit is FREE. 

Do NOT use Kerydin if you are pregnant, attempting to become pregnant, or at a high risk of becoming pregnant. Kerydin (tavaborole)  is a Pregnancy Kerydin is pregnancy category C, and should be used during pregnancy.
• Do NOT use Kerydin if you are breast feeding.
• Do NOT use Kerydin if you are allergic  or sensitive to any of the ingredients: tavaborole in a solution base alcohol, propylene glycol and edetate calcium disodium.
• Kerydin needs direct supervision if you have a history of immunosuppression or immune system disease, if you are HIV-positive, if you are on cancer chemotherapy treatment, or you have diabetes or diabetic neuropathy.
• Kerydin is contraindicated if you have severe case of nail fungus infection involving many nails and involving the entire nail to the cuticle with the nail crumbling and lifting from the nail bed accompanied by pain. You need to been seen by your physician or a podiatrist.
• Kerydin is NOT approved for pediatric use, and we do NOT prescribe Kerydin to anyone under the age of 18 
• Kerydin is ONLY approved for use on toenails.  Do NOT use on fingernails. Do NOT use in eyes, orally, on mucous membranes or in vaginal area.

• Kerydin Topical Solution is for EXTERNAL USE ONLY.  Avoid getting Kerydin in your eyes, nose or mouth.  Flush with water and seek immediate medical attention! Kerydin is for use on nails and surrounding skin only. Do not use Kerydin in your mouth, eyes, or vagina. Use it exactly as instructed by your doctor.
• Apply Kerydin Topical Solution only to toenails.  Do not apply intravaginally or to other areas of skin or to fingernails.
• Do NOT use nail polish, artificial nails, or any other cosmetic nail product on the nails with Kerydin Topical Solution.
• Do NOT combine topical Kerydin Topical Solution with any other systemic antifungal NAIL treatment.
• If the area of application shows signs of increased irritation such as increased redness, swelling, burning, blistering, or oozing, DISCONTINUE USE and seek immediate medical attention from your regular physician.
• Kerydin is to be used as part of a comprehensive nail care program. 
• Kerydin topical solution is flammable. Keep away from heat and flame. Avoid heat and flame while applying Kerydin to your toenail.
• Keep away from children.
• If you get the medication in your eyes, rinse immediately with water and contact your regular physician or seek emergency medical treatment! 
• There are NO systemic effects when used appropriately

 
Kerydin is a topically applied solution with negligible systemic absorption and no liver monitoring required
 
    No need for patient counseling for potential liver toxicity
    No need for liver function tests
    In vitro liver enzyme studies show that drug interactions are not expected

Kerydin is an oxaborole antifungal dosed once daily for 48 weeks for the treatment of onychomycosis of the toenail(s). Kerydin is specifically formulated to reach the site of the onychomycosis, to treat toenail fungal infections. Kerydin reaches the nail bed and the site of infections when applied as directed via broad coverage of multiple pathways and works via inhibition of protein synthesis. 
 

HOW TO APPLY Kerydin with its dropper applicator:

• Your toenails should be clean and dry before you apply Kerydin.

• Before you apply Kerydin to your affected toenail for the first time, remove the bottle cap and wrapping from the dropper and throw it away. Insert the dropper into the Kerydin bottle.


 
•  STEP 1:  Before you apply Kerydin to your affected toenail, remove the cap from the Kerydin bottle and squeeze to top to get the Kerydin into the dropper.


 
• STEP 2: Hold the dropper over the affected toenail, and apply one or more drops to cover the nail.


 
• STEP 3: Using the dropper tip, spread the Kerydin over the toenail


 
 
• STEP 4: Apply Kerydin under the toenails. Also use the dropper to spread Kerydin under the entire tip of the toenail.


 
• Allow a couple of minutes for toenails to dry completely.
• Repeat steps 1 through 4 for each affected toenail.
• Use a tissue to wipe any excess solution from the surrounding skin. Do NOT wipe Kerydin off your toenails.

 
• Step 5: After applying Kerydin to your affected toenails,  insert the dropper back into the bottle, screw it on tightly. 


 
• Step 6: Wash your hands with soap and water after applying Kerydin.

Sticking With Treatment

Kerydin should be applied once daily for 48 weeks, exactly as directed by your doctor. It may be useful for you to establish a routine or daily treatment time to help you stick to your treatment, such as:

    When you wake up in the morning
    After you shower*
    Just before bed

*Wait for at least 10 minutes after showering, bathing, or washing before applying Kerydin.

• The  majority of patients using Kerydin Topical Solution experience no side effects, any side effects are mild if any.  The side effects when used topically as directed are limited to:

 

 

Adverse events reported by >1% of subjects in Phase 3 studies:

Ingrown toenail (2.5% vs 0.3% with vehicle)
Application-site exfoliation (2.7% vs 0.3% with vehicle)
Application-site erythema (1.6% vs 0% with vehicle)
Application-site dermatitis  (1.3% vs 0% with vehicle)